ONCAlert | 2018 Gastrointestinal Cancers Symposium
Videos  >  

The Future of the Treatment of TNBC

Sara Hurvitz, MD
Published Online:11:47 AM, Thu October 23, 2014
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).

Clinical Pearls

  • BRCA-like or basal-like breast cancer that is triple-negative is particularly aggressive. Platinums may be more effective in this space.
  • Many pharmaceutical companies are not looking at PARP inhibitors in large studies because of the results of 1 negative trial.
  • Many TNBCs have downregulation of BRCA proteins where inhibiting PARP may be particularly effective.
  • Some studies are also looking at antibodies and antibody-directed therapies to inhibit the NOTCH pathway.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.